Apogee Therapeutics to Participate in Upcoming November Investor Conferences
SAN FRANCISCO and WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, asthma, chronic obstructive pulmonary disease and other inflammatory and immunology indications, today announced that management will present at the following upcoming investor conferences:
Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference
Date: Monday, November 6, 2023
Time: 2:30 p.m. ET
Stifel 2023 Healthcare Conference
Date: Tuesday, November 14, 2023
Time: 10:20 a.m. ET
Jefferies London Healthcare Conference
Date: Wednesday, November 15, 2023
Time: 11:30 a.m. ET
Evercore ISI 6th Annual HealthCONx Conference
Date: Tuesday, November 28, 2023
Time: 11:15 a.m. ET
A live and archived webcast of the fireside chats and presentations will be available via the page in the Investors section of the Apogee Therapeutics website.
About Apogee Therapeutics
Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit .
Investor Contacts:
Noel Kurdi
VP of Investor Relations
Apogee Therapeutics
Bill Slattery
THRUST Strategic Communications
Media Contact:
Dan Budwick 1AB Media
